Quartz·1 min read·medium
Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal
✦AI Summary
Tempus AI is set to acquire cancer-monitoring firm Personalis in an all-stock deal valued at $1.5 billion. The acquisition grants Tempus access to Personalis' proprietary NeXT Personal cancer detection technology.
The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test
businesstechnologyhealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in